Form 4: Personalis CEO Sells Shares Under 10b5-1 Plan

Christopher M. Hall, CEO of Personalis, Inc., reported transactions involving the sale of common stock and the exercise of stock options under a pre-arranged 10b5-1 trading plan.

Summary

• Christopher M. Hall, CEO of Personalis, Inc., executed a Rule 10b5-1 trading plan on December 17, 2025.
• On July 9, 2026, Hall acquired 100,000 shares of common stock at $1.61 per share.
• On the same date, Hall sold 100,000 shares of common stock at a weighted average price of $15.08 per share, with individual sale prices ranging from $15.00 to $15.24.
• Following these transactions, Hall beneficially owns 235,986 shares of common stock.
• Additionally, Hall exercised stock options to acquire 66,667 shares and 33,333 shares.
• The options for 66,667 shares vested over a three-year period starting April 15, 2024.
• The options for 33,333 shares are fully vested and exercisable.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While the CEO is selling a significant number of shares, it is executed under a Rule 10b5-1 plan, which is a standard and legally protected method for insiders to trade securities.

Positives

• The transactions were conducted under a Rule 10b5-1 trading plan, which is designed to provide an affirmative defense against allegations of insider trading.
• The CEO exercised options and sold shares, indicating potential liquidity events or strategic portfolio management.
• Some of the exercised options were for shares that are fully vested.

Negatives

• The CEO sold a significant number of shares (100,000) at a price considerably higher than the exercise price of the options used to acquire them.
• The weighted average sale price of $15.08 is substantially higher than the exercise price of $1.61 for the acquired shares.

Risks

• The sale of a large number of shares by the CEO could be interpreted negatively by the market, potentially impacting share price.
• While conducted under a 10b5-1 plan, the timing and volume of sales could still raise concerns among investors about the CEO's confidence in future performance.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance regarding the company's future performance. The information pertains to past transactions executed under a pre-defined plan.

Management Comments

• The sales and option exercise reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 17, 2025.
• The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $15.00 to $15.24 per share.
• Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
• The option vested and became exercisable over the three-year period commencing April 15, 2024, with 1/36th of the shares subject to the option vesting each month of continuous service thereafter.
• The shares subject to the option are fully vested and exercisable.

Industry Context

StockSavvy.ai notes that Form 4 filings detailing insider transactions under Rule 10b5-1 plans are common in the biotechnology and life sciences sector, where executive compensation often includes stock options and the market can be volatile. Such plans are crucial for executives to diversify holdings or manage personal finances without triggering insider trading concerns.

Stakeholder Impact

• Shareholders: May view the CEO's sale of a large number of shares with caution, potentially leading to short-term price pressure, despite the 10b5-1 plan. However, the plan itself is a governance mechanism to allow for orderly trading.
• Employees: May interpret the CEO's stock sales as a signal, though the 10b5-1 plan mitigates direct negative implications.
• Management: The execution of the 10b5-1 plan demonstrates adherence to corporate governance best practices for insider trading.

Next Steps

• The reporting person will continue to adhere to the terms of the Rule 10b5-1 trading plan.
• The company may provide further information regarding share sales at specific prices upon request from regulatory bodies or security holders.

Key Dates

Recommendation

The filing reports insider transactions under a Rule 10b5-1 plan, which is a standard mechanism for executives to manage their stock holdings. While the sale of a significant number of shares by the CEO could be a point of concern, the pre-planned nature of the trades under the 10b5-1 plan suggests it is not necessarily a reflection of negative sentiment towards the company's future prospects. Therefore, a 'hold' recommendation is appropriate, pending further company performance data.

Keywords

Personalis, PSNL, Form 4, Insider Trading, 10b5-1 Plan, Stock Options, Share Sale, Beneficial Ownership, Christopher M. Hall, SEC Filing